a 501(c)(3) educational nonprofit organization

2 0 1 3 A N N U A L R E P O R T

The 2013 Meeting SeasonPulmonary Vascular Disease and Right Ventricular Dysfunction: Current Concepts and Future Therapies (S1) September 10–15, 2012 | Portola Hotel & Spa | Monterey, California, USA Aging and Diseases of Aging (S2)October 22–27, 2012 | Sheraton Miyako Hotel Tokyo | Tokyo, JapanImmunological Mechanisms of Vaccination (S3)December 13–18, 2012 | Fairmont Château Laurier | Ottawa, Ontario, CanadaType 2 Immunity: Initiation, Maintenance, Homeostasis and Pathology (J1) joint with Pathogenic Processes in Asthma and COPD (J2) January 10–15, 2013 | Santa Fe Community Convention Center | Santa Fe, New Mexico, USA Multiple Sclerosis (A1) January 11–16, 2013 | Big Sky Resort | Big Sky, Montana, USA New Frontiers in Cardiovascular Genetics beyond GWAS (A2)January 13–18, 2013 | Granlibakken Resort | Tahoe City, California, USA Frontiers of NMR in Biology (A3) January 13–18, 2013 | Snowbird Resort | Snowbird, Utah, USA Hematopoiesis (A4) January 14–19, 2013 | Sheraton Steamboat Resort | Steamboat Springs, Colorado, USA Emerging Topics in Immune System Plasticity: Cellular Networks, Metabolic Control and Regeneration (A5) January 15–20, 2013 | Santa Fe Community Convention Center | Santa Fe, New Mexico, USA Plant Abiotic Stress and Sustainable Agriculture: Translating Basic Understanding to Food Production (A6) January 17–22, 2013 | Sagebrush Inn and Conference Center | Taos, New Mexico, USA Noncoding RNAs in Development and Cancer (A7) January 20–25, 2013 | Fairmont Hotel Vancouver | Vancouver, British Columbia, Canada Malaria (A8) January 20–25, 2013 | JW Marriott New Orleans | New Orleans, Louisiana, USA Metabolic Control of Inflammation and Immunity (A9) January 21–26, 2013 | Beaver Run Resort | Breckenridge, Colorado, USA Antibodies as Drugs (J3) joint with Cancer Immunology and Immunotherapy (J4) January 27–February 1, 2013 | Fairmont Hotel Vancouver | Vancouver, British Columbia, CanadaAdipose Tissue Biology (J5) joint with Diabetes – New Insights into Mechanism of Disease and Its Treatment (J6)January 27–February 1, 2013 | Keystone Resort | Keystone, Colorado, USA Mitochondria, Metabolism and Myocardial Function – Basic Advances to Translational Studies (B1) February 3–8, 2013 | Keystone Resort | Keystone, Colorado, USA Neurogenesis (J7) joint with New Frontiers in Neurodegenerative Disease Research (J8) February 3–8, 2013 | Santa Fe Community Convention Center | Santa Fe, New Mexico, USA Lung Development, Cancer and Disease (B2) February 5–10, 2013 | Sagebrush Inn and Conference Center | Taos, New Mexico, USA The Gut Microbiome: The Effector/Regulatory Immune Network (B3) February 10–15, 2013 | Sagebrush Inn and Conference Center | Taos, New Mexico, USA B Cell Development and Function (X1) joint with HIV Vaccines (X2) February 10–15, 2013 | Keystone Resort | Keystone, Colorado, USA Autophagy, Inflammation and Immunity (B4) February 17–22, 2013 | Fairmont The Queen Elizabeth | Montreal, Québec, Canada

Nutrition, Epigenetics and Human Disease (B5) February 19–24, 2013 | Hilton Santa Fe/Historic Plaza | Santa Fe, New Mexico, USA Myeloid Cells: Regulation and Inflammation (B6) February 19–24, 2013 | Keystone Resort | Keystone, Colorado, USA Stem Cell Regulation in Homeostasis and Disease (B7) February 24–March 1, 2013 | Fairmont Banff Springs | Banff, Alberta, Canada PI 3-Kinase and Interplay with Other Signaling Pathways (X3) joint with Tumor Metabolism (X4) February 24–March 1, 2013 | Keystone Resort | Keystone, Colorado, USA Structural Analysis of Supramolecular Assemblies by Hybrid Methods (C1) March 3–7, 2013 | Granlibakken Resort | Tahoe City, California, USA Understanding Dendritic Cell Biology to Advance Disease Therapies (C2) March 3–8, 2013 | Keystone Resort | Keystone, Colorado, USA DNA Replication and Recombination (X5) joint with Genomic Instability and DNA Repair (X6) March 3–8, 2013 | Fairmont Banff Springs | Banff, Alberta, Canada Growing to Extremes: Cell Biology and Pathology of Axons (C4) March 10–15, 2013 | Granlibakken Resort | Tahoe City, California, USA Host Response in Tuberculosis (X7) joint with Tuberculosis: Understanding the Enemy (X8) March 13–18, 2013 | Whistler Conference Centre | Whistler, British Columbia, Canada Precision Genome Engineering and Synthetic Biology: Designing Genomes and Pathways (C5) March 17–22, 2013 | Beaver Run Resort | Breckenridge, Colorado, USA Neuronal Control of Appetite, Metabolism and Weight (C6) March 17–22, 2013 | Fairmont Banff Springs | Banff, Alberta, Canada RNA Silencing (C7) March 19–24, 2013 | Whistler Conference Centre | Whistler, British Columbia, Canada Epigenetic Marks and Cancer Drugs (C8) March 20–25, 2013 | Eldorado Hotel & Spa | Santa Fe, New Mexico, USA Molecular Clockworks and the Regulation of Cardio-Metabolic Function (C9) Apr 3–7, 2013 | Snowbird Resort | Snowbird, Utah, USA Immune Activation in HIV Infection: Basic Mechanisms and Clinical Implications (D2) April 3–8, 2013 | Beaver Run Resort | Breckenridge, Colorado, USA Nuclear Receptors and Friends: Roles in Energy Homeostasis and Metabolic Dysfunction (D3) April 3–8, 2013 | Alpbach Congress Centrum | Alpbach, Austria Immunopathology of Type 1 Diabetes (Z1) joint with Advances in the Knowledge and Treatment of Autoimmunity (Z2) April 4–9, 2013 | Fairmont Chateau Whistler | Whistler, British Columbia, Canada Cardiac Remodeling, Signaling, Matrix and Heart Function (D4) April 7–12, 2013 | Snowbird Resort | Snowbird, Utah, USA Plant Immunity: Pathways and Translation (D5) April 7–12, 2013 | Big Sky Resort | Big Sky, Montana, USA Positive Strand RNA Viruses (D7) April 28–May 3, 2013 | Boston Park Plaza & Towers | Boston, Massachusetts, USA The Innate Immune Response in the Pathogenesis of Infectious Disease (E1) May 10–15, 2013 | Centro de Artes e Convenções (UFOP) | Ouro Preto, BrazilThe Hippo Tumor Suppressor Network: From Organ Size Control to Stem Cells and Cancer (E2) May 19–23, 2013 | Hyatt Regency Monterey | Monterey, California, USAHuman Genomics and Personalized Medicine (E3) June 17–22, 2013 | Clarion Hotel Sign | Stockholm, Sweden

Fiscal year 2013 was another very good year for Keystone Symposia in spite of fears about ongoing economic stagnation and reduced government funding for science. While we had a slight decrease in government grant funding, we saw an overall increase in funding from

all sources. Thank you to all the corporate, foundation, government and individual donor sources listed toward the end of this Report who enable us to fulfill our mission. Approximately 35% of our funding comes from such sources with the remainder from conference registration fees. The funding enables us to keep registration fees lower than they would otherwise be while also offering scholarships to deserving students and postdoctoral fellows, plus travel awards for investigators from low and middle income countries to attend meetings in the Global Health Series.

With the upcoming retirement next year of CEO James Aiken and the conclusion of Keystone Symposia’s 40-year anniversary in 2012, the organization is preparing for change and new growth. I along with the other Board members would like to thank Dr. Aiken for the outstanding leadership and steady guidance he has provided to Keystone Symposia for the past 10 years.

We look to the future with optimism and confidence about the important and vital role Keystone Symposia will continue to play in life science research.

Sincerely,

Juleen R. Zierath, Ph.D.Chair, Board of Directors, Keystone Symposia and Professor, Karolinska Institutet

In fiscal year 2013, due to uncertainties about the economy at large and because we program two years in advance, we were more conservative with our meeting portfolio, reducing the number of conferences to 53, versus 55 in fiscal year 2012. We ended the year with a slight

increase in the number of total attendees, and the average number of abstracts submitted per meeting was actually one off its all-time high. In spite of our caution, we nevertheless held a number of conferences on important new topics, including “Pulmonary Vascular Disease and Right Ventricular Dysfunction,” “Nutrition, Epigenetics and Human Disease,” “Positive Strand RNA Viruses” and “Human Genomics and Personalized Medicine.” We also held meetings in various new locations for us such as Kyoto, Japan; Montreal, Canada; New Orleans, USA; and Ouro Preto, Brazil – the first time for us on the South American continent. The generous corporate support we receive via our discretionary Directors’ Fund allows us to program these new “experiments” even though they are unlikely to break-even on a standalone basis. In fact, corporate support reached a new record level, and several companies moved up to our new “Champion” level at $100,000 of annual support. For this we were very grateful. We are also appreciative of all those individual donors and industry speakers who forego reimbursement to support our scholarship program, since it did become necessary to use less of our general funds for scholarships in 2013. Fortunately, despite giving fewer scholarships, 39% of our attendees were students and postdoctoral fellows, about on par with previous years.

This is my last full fiscal year as CEO of Keystone Symposia; I will be retiring in spring 2014 after an extremely enjoyable and rewarding decade at the organization’s helm. I would like to personally thank the staff, Board of Directors, Scientific Advisory Board, financial donors, and all the many scientific organizers and speakers who make it possible for the organization to fulfill its mission. They have made my job a real pleasure I will be sorry to leave behind. Last but not least, I would like to thank all the participants from academia, industry, and the government and nonprofit sectors who take the time out of their busy schedules to attend the meetings, often traveling great distances to do so. Without this participation, the meetings would not be the vibrant and dynamic events that they invariably are. Sincerely,

James W. Aiken, Ph.D.President and Chief Executive Officer, Keystone Symposia

From the Chair of the Board

From the Chief Executive Officer

3

2013 EXPENSE BREAKDOWN

The charts below are intended to provide a snapshot of Keystone Symposia’s 2013 finances and activities. Please visit keystonesymposia.org/AboutUs/AnnualReport.cfm to view the full audited statement of financial condition and statement of activities for the fiscal year July 1, 2012 – June 30, 2013.

2013 REVENUE BREAKDOWN

Investment Income/Miscellaneous Income (11.14%)

Corporate & Foundation Gifts (20.49%)

Government Grants (5.56%)

Individual Gifts (.38%)

Registration Fees/Earned Income(62.43%)

4

81% of Keystone Symposia’s expenditures in fiscal year 2013 went toward educational programs including meeting programs, scholarships, travel awards and diversity initiatives.

Breakdown of the Year

Educational Programs (81.05%)

Fundraising & Development (3.68%)

Management & General (15.27%)

2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013

13,956

7,340

13,509

6,587

13,015

5,962

11,512

5,736

11,222

5,400

10,329

5,060

Attendees & Speakers

Abstract Submissions*

2003 2004 2005 2006 2007 2008 2009 2010 2011* 2012* 2013*

929903

711681

619

546

459

Scholarships

Underrepresented Trainee Scholarships& Travel Awards

Global Health Travel Awards

TOTAL MEETING ATTENDANCE & ABSTRACT SUBMISSIONS*

SCHOLARSHIPS & TRAVEL AWARDS

12,303

6,547

930

5

AVERAGE ATTENDANCE & ABSTRACTS* PER MEETING

2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013

Average Attendance

Average Number of Abstracts*

58565054444641 52

6,857

13,554

252 244262

241

270242 241 237

123 117 130110

132 122 127 126Number of Meetings

*abstract count does not include speaker abstracts

*abstract count does not include speaker abstracts

13,770

7,381

55

250

134

882*

*Scholarship amount was increased from $1,000 to $1,200 in 2011, which reduced the total number awarded.

12,360

7,031

55

225

120

835*

12,579

6,603

237

133

53

623*

MEETING “EXCELLENT” RATINGS AS A PERCENT OF ALL RATINGS (BASED ON ATTENDEE SURVEYS)

VALUE PARTICIPANTS GAINED FROM THE 2013 MEETINGS (BASED ON ATTENDEE SURVEYS)

Poster/Abstract Quality

Quality of Plenary Speakers

Overall Scientific Content Quality

60%

55%

50%

45%

40%

35%

30%

25%

20% 2007 2008 2009 2010 2011 2012 2013

Made a Useful Contact Saved Research Time/Money or Meeting Facilitated Accelerated Research Objectives Junior-Senior Interactions (N=4,258) (N=4,258) (N=4,258)

6

79%

15%

5%

34%

51%

14%

Agree

Neutral or N/A

Disagree

PARTICIPATION OF THE NEXT GENERATION OF INVESTIGATORS (PERCENT OF TOTAL & ABSOLUTE NUMBERS)

2008 2009 2010 2011 2012 2013

64(4%)

109(7%)

92(7%)

130(9%)

Assistant Professor & Young Investigator Speakers & Organizers

Total Assistant Professor & Young Investigator Attendees

Total Student & Postdoctoral Fellow Attendees

1,143(8%)

1,104(9%)

1,403(10%)

5,415(39%)

4,930(40%)

5,564(41%)

941(7%)

5,368(40%)

160(11%)

1,222(10%)

4,679(38%)

4%8%

87%

4,863(39%)

1,388(11%)

111(7%)

Keystone Symposia is fortunate to receive substantial ongoing support from the pharmaceutical and biotechnology industries, charitable foundations and individuals. We are also honored to be the recipient of numerous grants from the US National Institutes of Health and other government agencies around the world. These gifts and grants are used to provide

scholarships for graduate students and postdoctoral fellows, travel awards for scientists from developing nations and subsidies for the travel and lodging costs of scientific speakers from academic and other nonprofit laboratories and institutions.

For the 2013 meeting season and fiscal year, we received a total of $4.6 million from government, corporate, foundation and individual sources, as shown in the chart below. This funding is crucial in supporting Keystone Symposia’s mission to serve as a catalyst for the advancement of biomedical and life sciences and to accelerate applications that benefit humankind.

Keystone Symposia gratefully acknowledges donors who gave in the 2013 fiscal year. Their generous support makes possible the outstanding scientific quality of our meetings and unsurpassed opportunities for interaction and collaboration among participants. To make a gift, please contact the Development office by telephone at 970.262.2690 or by e-mail at development@keystonesymposia.org. “Future of Science Fund” individual donations can also be made over the Internet at www.keystonesymposia.org/ScienceFund.

Christopher Atwood, D.Min.Director of Development, Keystone Symposia

7

Assistant Professor & Young Investigator Speakers & Organizers

Total Assistant Professor & Young Investigator Attendees

Total Student & Postdoctoral Fellow Attendees

Donor Support

Corporate Gifts: $1,523,033 (33%)

Foundation Gifts: $1,191,355(26%)

US Federal Government Grants: $767,925(17%)

Other Government Grants: $155,033 (3%)

In-Kind Gifts:$923,455(20%)

Individual Gifts: $53,742 (1%)

CHAMPIONSTop-tier donors making an ongoing, annual commitment of $100,000+. Their public championing of Keystone Symposia’s cause provides inspirational leadership commitment to our shared scientific mission of catalyzing collaborations, accelerating discoveries, and preparing and positioning the next generation of leading life scientists.

Educational donation provided by Amgen*Bayer USA Foundation*Bill & Melinda Gates FoundationCNPq – the National Council for Scientific and Technological Development, BrazilEMD Millipore*

SUSTAINING BENEFACTORSDonors making a three-year commitment of at least $50,000 per year. Their generous support is crucial to sustain Keystone Symposia’s ability to plan future scientific conferences focused on emerging topics and excellence in science.

Cell Research*Takeda Pharmaceutical Company Limited*

BENEFACTORSDonors of $50,000 or above. We are very grateful for their extraordinary commitment to our mission to connect the scientific community and accelerate discoveries that benefit society. Special thanks to those organizations that provide consistent, annual Benefactor-level support.

AVEO Oncology*Genentech, Inc.*National Multiple Sclerosis SocietyNestlé Institute of Health Sciences*Pfizer Inc.*

SUSTAINING SPONSORSDonors making a three-year commitment of $25,000 to $49,999 per year. Their generous support is crucial to Keystone Symposia’s ability to plan future scientific conferences focused on emerging topics and excellence in science.

AbbVie Inc.*Astellas Pharma Inc.*Biogen Idec*Boehringer Ingelheim Pharmaceuticals, Inc.*Celgene Corporation*Gilead Sciences, Inc.*H3 Biomedicine Inc.*Infinity Pharmaceuticals*

SPONSORSDonors contributing $25,000 to $49,999. These generous gifts allow us to convene meetings in a wide variety of important areas. Special thanks to those organizations that provide consistent, annual Sponsor-level support.

AstraZeneca*Bristol-Myers Squibb Company*GlaxoSmithKline*Isis Pharmaceuticals, Inc.*Janssen R&D, Pharmaceutical Companies of Johnson & Johnson*Japanese Society of Anti-Aging MedicineEducational grant from Lilly USA, LLC*

The listings on this page and the next five pages reflect donations for the fiscal year beginning July 1, 2012 and ending June 30, 2013.

8

Donor Support

Life Technologies Corporation* MedImmune* Onyx Pharmaceuticals, Inc.* Sangamo BioSciences, Inc.* Shire Human Genetic Therapies* Vertex Pharmaceuticals Incorporated*

Medicines for Malaria Venture – Ian Bathurst Global Health Travel Awards Monsanto Company* Novartis Pharma K.K. Novo Nordisk A/S* Sanofi US*

FAPEMIG – Minas Gerais State Agency for Development ResearchMerck & Co., Inc.*Science for Life Laboratory – StockholmKnut and Alice Wallenberg Foundation

The listings on this page and the next five pages reflect donations for the fiscal year beginning July 1, 2012 and ending June 30, 2013.

*Indicates a gift to the Directors’ Fund, which allows Keystone Symposia’s President/CEO and Directors to schedule and support meetings in the early stages of research.

9

PARTNERS, PATRONS, DONORS AND CONTRIBUTORS

Keystone Symposia wishes to thank the following donors to the 2013 meeting series. Their generous support makes possible the outstanding scientific quality of our meetings and unsurpassed opportunities for interaction among attending scientists.

PARTNERS($10,000–$24,999)

Cell Signaling Technology, Inc.The Ellison Medical FoundationLandes Bioscience*March of Dimes FoundationThe Company of Biologists Ltd

PATRONS($5,000–$9,999)

AdipoGen International*Avanti Polar Lipids, Inc.*BioLegend*CEDARLANE*Crohn’s & Colitis Foundation of AmericaDAIICHI SANKYO CO., LTD.*Exiqon A/S*Inoue Foundation for ScienceIntegrated DNA Technologies*

DIRECTORS’ FUND CHAMPIONS & BENEFACTORSThe following donors with unrestricted gifts of $50,000 or more enabled Keystone Symposia’s President/CEO and Directors to schedule meetings in a variety of important areas, many of which are in the early stages of research.

AVEO Oncology Educational donation provided by AmgenBayer USA FoundationCell Research EMD Millipore

DIRECTORS’ FUND SPONSORSThe following donors with unrestricted gifts from $25,000 to $49,999 also provided invaluable support to the Directors’ Fund.

AbbVie Inc.Astellas Pharma Inc.AstraZeneca Biogen IdecBoehringer Ingelheim Pharmaceuticals, Inc.Bristol-Myers Squibb Company Celgene CorporationGilead Sciences, Inc.GlaxoSmithKline H3 Biomedicine Inc.Infinity PharmaceuticalsIsis Pharmaceuticals, Inc.

JDRF The Naito Foundation Novus Biologicals, Inc.* Ono Pharmaceutical Co. Ltd. ROCKLAND IMMUNOCHEMICALS, Inc.* Seahorse Bioscience, Inc.* Sigma Life Science* Tourisme Montréal Zymo Research Corporation*Medicines for Malaria Venture – Ian Bathurst Global

Health Travel Awards Monsanto Company* Novartis Pharma K.K. Novo Nordisk A/S* Sanofi US*

Genentech, Inc.Merck & Co., Inc.Nestlé Institute of Health Sciences Pfizer Inc.Takeda Pharmaceutical Company Limited

Janssen R&D, Pharmaceutical Companies of Johnson & Johnson Life Technologies CorporationEducational grant from Lilly USA, LLC MedImmuneMonsanto Company Novo Nordisk A/S Onyx Pharmaceuticals, Inc.Sangamo BioSciences, Inc.Sanofi USShire Human Genetic TherapiesVertex Pharmaceuticals Incorporated

ImmunoGen, Inc.*International Symposium on Positive Strand RNA VirusesISOTEC, a member of the Sigma-Aldrich Group*KWS SAAT AG*MISSION Therapeutics Limited*Myriad-RBM*Opsona Therapeutics Ltd*Promega Corporation*R&D Systems, Inc.*The Rockefeller University Press – The Journal of Experimental Medicine*Seattle Genetics, Inc.*STEMCELL Technologies, Inc.*Syngenta Biotechnology, Inc.*Thermo Fisher Scientific, Inc.*

US GOVERNMENT GRANTS

Keystone Symposia appreciates grants to support various 2013 meetings received from the following government agencies:

National Institutes of Health (NIH):National Cancer Institute (NCI)National Heart, Lung, and Blood Institute (NHLBI)National Institute on Aging (NIA)National Institute of Allergy and Infectious Diseases (NIAID)National Institute of Arthritis and Muscoskeletal and Skin Diseases (NIAMS)Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)National Institute of Environmental Health Sciences (NIEHS)National Institute of General Medical Sciences (NIGMS)National Institute of Neurological Disorders and Stroke (NINDS)

National Science Foundation (NSF)

*Indicates a gift to the Directors’ Fund, which allows Keystone Symposia’s President/CEO and Directors to schedule and support meetings in the early stages of research.

10

PARTNERS, PATRONS, DONORS AND CONTRIBUTORS (CONTINUED)

DONORS($2,500–$4,999)

Abcam plcAgilent Technologies*ALPCO Diagnostics*Alzheimer’s Drug Discovery FoundationAmerican Heart Association’s Council on Cardiopulmonary, Critical Care, Perioperative and ResuscitationBayer CropScience N.V.*BioVentures, Inc.*Bruker BioSpin Corporation*ChemoCentryx, Inc.*Chroma Technology Corporation*Cubist Pharmaceuticals, Inc.*Cytokinetics, Inc.*Epizyme, Inc.*Essential Pharmaceuticals*GenScript USA Inc.*

CONTRIBUTORS(up to $2,499)

American Heart Association’s Council on Basic Cardiovascular SciencesAmerican Heart Association’s Council on Cardiovascular Disease in the YoungAmerican Heart Association’s Council on Functional Genomics and Translational BiologyCambridge Isotope Laboratories*Echelon Biosciences, Inc.

Donor Support

GenVec, Inc.*InvivoSciences LLC*Journal of Lipid ResearchNew Era Enterprises, Inc.NMR-BioRigaku Americas Corporation*Science Translational Medicine

DIVERSITY PROGRAM SUPPORT

Keystone Symposia is grateful to the following 2013 supporters of its Diversity in Life Science Programs.

Biogen IdecNovartis Institutes for BioMedical Research

National Institute of General Medical Sciences (NIGMS), NIH, Minority Access to Research Careers (MARC)

11

These generous alumni of previous meetings and others with a passion for ensuring a future of scientific discovery that benefits humankind have made gifts in the fiscal year ending June 30, 2013 to support the Keystone Symposia Future of Science Fund. Through their generosity, we are able to provide scholarships and travel awards to the next generation of biomedical and life scientists, whose education and careers are enhanced by the opportunity to attend meetings and interact with the world’s leading senior scientists.

PRESIDENT’S CIRCLE ($10,000+)The Elkes Foundation

FOUNDERS’ SOCIETY ($5,000–$9,999)A.J. MillerDavid and Marcy Woodland

KEYSTONE CHAMPIONS ($1,000–$4,999)Jim and Sue AikenVishva DixitIn Honor of Jeffrey M. Gimble, M.D., Ph.D.Philip GregoryChris & Marsha Karp/Wills-Karp with matching gift from Bill & Melinda Gates FoundationMargaret Liu and Robert JohnsonSidney E. Frank FoundationJuleen R. Zierath

KEYSTONE BENEFACTORS ($500–$999)Christopher AtwoodKenneth W. BairMarilyn BairCintia De PaivaDr. C. A. MichieTerry J. OpgenorthIan A. Wilson

KEYSTONE PATRONS ($100–$499)Alan AttieRaymond BirgeLinda B. BloomRalph A. BradshawJeffrey BrophyJean-Francois CoutureRobert W. CraigHeidi DaetwylerPamela S. DaughertyPeter De HoffIn memory of Dr. Arline DeitchJesús DevesaThomas Dubensky, Jr.Brandt EichmanLee EllisBeverly M. EmersonStephan GasserHenry N. GinsbergDale HamiltonBarbara HansenPia HartmannLinda Hrycaj

Mark KaplanRolf KletzienShohei KoideMasayasu KojimaIrene KrummelTakeshi KuroseKevin LeggePatricia LiWangJonathan MooreRobert MurphyHeber NielsenAnders NykjaerDonal O’GormanEric Parker with matching gift from Merck Partership for Giving Alexander PertsemlidisBeverly RothemelAlejandro SánchezSusan ScottAnish Sen Majumdar, Ph.D.Alan SherSteven L. ReinerGerald SufrinTatyana SysoevaJames B. TragerTerry UntermanHarry van SteegTrudi VeldmanSally Wenzel-MorganrothJudith WhiteMatthew WilkersonZhongzhou YangAnonymous (3)

KEYSTONE CONTRIBUTORS($10–$99)Yusuke AdachiSyed AhmedAisha AlkhinjiAlex AlmasanThierry AlquierSaad AlshammaryYutaka AmakoAndre AmbrosioSuzanne AndersonBen AppelmelkKevin and Kellan BarrIssam Ben-SahraAkshay A. BhingeDouglas Bishop

Bonnie B. Blomberg Maria Bono Joshua Boyce Thibaut Brugat Bernard Burke Astrid E. Cardona Bo Carlsson Lucia Cavelier Vemika Chandra Chu-Chung Chen Wei-June Chen Elena Chertova Hyun-Min Cho Arpita Chowdhury Brendan Classon Eleanor Click Paul Converse Xanthi Couroucli Edecio Cunha-Neto Anne Curtis Simon Davis Sabine De Silva Claudia Diaz-Camino Cristina Dieni Horng-Yunn Dou Konstantinos Drosatos Jacques Drouin Karen Duus David Edgell Brice Emanuelli Gaetano Faleo David Ferguson Veerle Fleskens Adam Friedman Lucio Gama Thomas Garner Vania Romero Gomez Veronica Gonzalez-Pena Johannes Gräff Charles Greenblatt Charles Grose Tania Habib Emina Halilbasic Kenji Harada Zavain Harriot Lora Heisler Ronald Hendrickson Andrea Hevener Stephane Illiano Shigeki Iwase

Keystone Symposia Future of Science Fund Donors

12

KEYSTONE CONTRIBUTORS(CONTINUED) Mi-Hyeon Jang Fuguo Jiang Ping Jiang Eun-Kyeong Jo Arne Lund Jørgensen Joanna Kaplon Hiroto Kawashima Rom Keshet Dineo Khabele Simran Khurana Dai-Jin Kim Hwa-Jung Kim Soo-Jeong Kim Evangelos Kiskinis Kaori Koga Suneil Koliwad Yoshihiro Komohara Dong Kong Masato Kubo Ashutosh Kumar Su-Min Kwak Nathalie Labrecque Andrew Lane Amale Laouar Seung-Pyo Lee Wang Lee Andrew M. Leidal Zuh-Jyh Lin Dede Lori Qun Lu Steven K. Lundy Ivan Luptak Thomas Alexander Lutz Hsinchieh Ma Carla Margulies Debora Marks Miles Markus Sandra Marmiroli Pedro Marrero Lijoy Mathew Rebecca Mathew Paria Mirmonsef Claudia Monaco Raul Mostoslavsky Philippe Mourrain Thomas Mueller Maki Nakayama Carlos Nogueras-Ortiz Sussan Nourshargh Mary Ann Osley

Neetha Parameswaran Jenish Patel Heike Petrul Georg Plum Elizabeth Quezada Robert Rambo Laurent Renia Nina Reuven Stephane Ricoult Jerry Ruth Laurent Sabbagh Joshua Saldivar Beatrice Saviola Bernhard Schermer Wilfried Schgoer Max Schubert Anusha Seneviratne Klaus Seuwen Jin Young Shin Jason Shohet Rosa Sierra Anna Sokolovska Wenxia Song Sandra C. Souza Marius Stan Yan Sun Maria Sunnerhagen Hiroshi Suzuki Eva Szabo Akihiko Taguchi Ming Tan Akira Tanaka Tetsuya Tanaka M. Taylor Andy Yen-Tung Teng Jordi Torrelles Aslan Turer Koki Ueda Toshihiro Umehara Jan van Benthem Anke van den berg Bruno Vaslin Steven Vuotto Carston Wagner Wei Wang Johnathan Whetstine Min Wu Blerta Xhemalce Min Xu Byung Youn Xiuren Zhang Yang Zhang

Keystone Symposia Future of Science Fund Donors

13

BENEFACTORS ($50,000+)

BioMed Central LtdCell PressNature Publishing GroupThe Scientist

SPONSORS ($25,000–$49,999)

American Association for the Advancement of Science (AAAS)Cold Spring Harbor Laboratory PressLandes BiosciencePLOSThe Rockefeller University Press – The Journal of Cell BiologyWiley-Blackwell

PARTNERS ($10,000–$24,999)

BioTechniquesEMBO (European Molecular Biology Organization)FOCIS (Federation of Clinical Immunology Societies)Malaria NexusMary Ann Liebert, Inc. PublishersProceedings of the National Academy of SciencesPubget Inc.S. Karger AGThe Company of Biologists LtdThe Rockefeller University Press – The Journal of Experimental Medicine

PATRONS ($5,000–$9,999)

S. Karger AG – CardiologyS. Karger AG – ISCN 2013S. Karger AG – Journal of Innate ImmunityS. Karger AG – RespirationThe Journal of Rheumatology

DONORS ($2,500–$4,999)

Genetic Engineering & Biotechnology NewsMalaria WorldThe Journal of Clinical Investigation

CONTRIBUTORS (up to $2,499)

Beatson Institute for Cancer ResearchCancer ImmunityMolecular Metabolism (Elsevier GmbH)Pulmonary Circulation / Pulmonary Vascular Research InstitutePulmonary Hypertension AssociationSociety for Mucosal ImmunologyThe Protein Society

The following publishers, societies and other organizations provided in-kind marketing and advertising support that helped publicize the 2013 Keystone Symposia meeting series.

The following organizations generously agreed to forego reimbursements for speaker travel and lodging expenses in order to support 2013 Keystone Symposia meeting programs.

Bristol-Myers Squibb CompanyConstellation Pharmaceuticals Cytokinetics, Inc.Dynavax Technologies CorporationEpizyme, Inc.FibroGen IncorporatedGenentech, Inc.Immunocore LimitedImmusanT, Inc.Intercept Pharmaceuticals Inc.Keio University School of MedicineLS9, Inc.Max Planck Institute of BiochemistryMedImmune

Meiji UniversityMerck & Co., Inc.Micromet, Inc.Monsanto CompanyNestlé Institute of Health SciencesNovartis Institutes for BioMedical ResearchNovartis Vaccines and DiagnosticsPiramal Imaging GmbHSangamo BioSciences, Inc.Syngenta Biotechnology, Inc.Tokyo Medical and Dental UniversityTokyo Metropolitan Institute of Medical ScienceUniversity of California, San FranciscoUniversity of Florida

MARKETING/ADVERTISING IN-KIND DONORS

SPEAKER GIFT-IN-KIND DONORS

Keystone Symposia In-Kind Donors

Juleen R. Zierath, Ph.D.Chair of the Board, Keystone SymposiaProfessor, Molecular Medicine and Surgery, Karolinska Institutet

Gary J. Nabel, M.D., Ph.D. Secretary of the Board Chair, Scientific Advisory Board Chief Scientific Officer, Research and Development Sanofi

Terry J. Opgenorth, Ph.D.Treasurer of the BoardChair, Finance Committee, Keystone SymposiaChief Operating Officer, NeoTREXCSU Ventures, Inc., Colorado State University

James W. Aiken, Ph.D.President and Chief Executive OfficerKeystone Symposia on Molecular and Cellular Biology

David L. Woodland, Ph.D.Chief Scientific OfficerKeystone Symposia on Molecular and Cellular Biology

E. Dale Abel, M.D., Ph.D. H.A. and Edna Benning Presidential Endowed Professor of Endocrinology and Diabetes Professor of Medicine, Biochemistry & Human Genetics Senior Investigator, Program in Molecular Medicine Chief, Division of Endocrinology Metabolism and Diabetes University of Utah School of Medicine

Kenneth W. Bair, Ph.D.Chair, Development Committee, Keystone SymposiaSenior Vice President and Head, Research and Development Forma Therapeutics, Inc.

Vishva M. Dixit, M.D. Vice President, Early Discovery Research and Physiological Chemistry Genentech, Inc.

Beverly M. Emerson, Ph.D.Chair, Personnel Committee, Keystone SymposiaProfessor, Regulatory Biology LaboratoryThe Salk Institute

Peter M. Finan, Ph.D.Chair, Audit Committee, Keystone SymposiaDirector, Pathways Biology, Developmental and Molecular PathwaysNovartis Institutes for BioMedical Research

Heidi E. Hamm, Ph.D.Chair, Globalization Committee, Keystone SymposiaProfessor and Chair, Department of PharmacologyVanderbilt University School of Medicine

Edison T. Liu, M.D.President and Chief Executive OfficerThe Jackson Laboratory

Tony Pawson, Ph.D.Senior InvestigatorCentre for Systems Biology, Samuel Lunenfeld Research Institute

Alan Sher, Ph.D.Chair, Nominating Committee, Keystone SymposiaBethesda, Maryland

Ian A. Wilson, Ph.D., Sc.D., FRSProfessor, Department of Molecular Biology and The Skaggs Institute for Chemical BiologyThe Scripps Research Institute

Tadataka Yamada, M.D. Board Member, Executive Vice President and Chief Medical and Scientific Officer Takeda Pharmaceuticals

EMERITUS BOARD MEMBERS

Ralph A. Bradshaw, Ph.D.Professor Emeritus, Physiology and BiophysicsCollege of Medicine, University of California, IrvineProfessor in Pharmaceutical Chemistry and Deputy Director of Mass Spectrometry Facility, University of California, San Francisco

Robert W. CraigPresident Emeritus, The Keystone Center

Edward A. Dennis, Ph.D.Professor, Chemistry, Biochemistry and PharmacologySchool of Medicine, University of California, San Diego

Curtis C. Harris, M.D.Chief, Laboratory of Human CarcinogenesisNCI/National Institutes of Health

Note: All Board and Emeritus Board Members are also members of Keystone Symposia’s Scientific Advisory Board.

James Aiken, Chief Executive OfficerPamela Daugherty, Chief Financial OfficerDavid Woodland, Chief Scientific OfficerJeannie Dalrymple, Senior Director, Program Development & ImplementationLinda Hrycaj, Senior Director, Strategic PlanningChristopher Atwood, Director, Development Heidi Daetwyler-Simpson, Director, Meeting ManagementLaina King, Director, Diversity in Life Science ProgramsTanya Muller, Director, Information TechnologyYvonne Psaila, Director, Marketing & CommunicationsMary Jo Roal, Director, Human Resources

David Adamson, On-Site RepresentativeCathy Banks, Web Developer/Systems AnalystCarol Bosserman, On-Site RepresentativeMary Brown, On-Site RepresentativeCaroline Brendel, Executive Administrative AssistantLinda Cooper, Publications AssistantDoug Castle, Information Technology Programmer

Amanda Deem, Assistant Director of DevelopmentHeather Gerhart, Senior Grants Coordinator/Program AnalystSusan Gunn, Seasonal Logistics Assistant Lindsey Heilmann, Conference CoordinatorJenny Hindorff, Program Implementation AssociateSarah Lavicka, Assistant Director of DevelopmentJeff Lehman, Scholarship CoordinatorPhyllis McNeil, Attendee Services RepresentativeAllison Ogdon, Program Development CoordinatorAnnie Page, On-Site RepresentativeMcKennzie Rains, IT Support/AssistantGrace Roath, Office ManagerJulie Roll, On-Site RepresentativeDavid Sanchez, Manager, Attendee Services Barbara Schmid-Miller, Program Implementation AssistantGwyn Schmude, Attendee Services RepresentativeDawn Shafer, Accounting ClerkBridget Stacy, Administrative Assistant, DiversityKathy Tavares, Program Development/Implementation SupervisorRebecca Wilkerson, Finance Assistant

14

Board of Directors (as of June 30, 2013)

Staff (as of June 30, 2013)

Heidi E. Hamm, Ph.D.Chair, Globalization Committee, Keystone SymposiaProfessor and Chair, Department of PharmacologyVanderbilt University School of Medicine

Edison T. Liu, M.D.President and Chief Executive OfficerThe Jackson Laboratory

Tony Pawson, Ph.D.Senior InvestigatorCentre for Systems Biology, Samuel Lunenfeld Research Institute

Alan Sher, Ph.D.Chair, Nominating Committee, Keystone SymposiaBethesda, Maryland

Ian A. Wilson, Ph.D., Sc.D., FRSProfessor, Department of Molecular Biology and The Skaggs Institute for Chemical BiologyThe Scripps Research Institute

Tadataka Yamada, M.D. Board Member, Executive Vice President and Chief Medical and Scientific Officer Takeda Pharmaceuticals

EMERITUS BOARD MEMBERS

Ralph A. Bradshaw, Ph.D.Professor Emeritus, Physiology and BiophysicsCollege of Medicine, University of California, IrvineProfessor in Pharmaceutical Chemistry and Deputy Director of Mass Spectrometry Facility, University of California, San Francisco

Robert W. CraigPresident Emeritus, The Keystone Center

Edward A. Dennis, Ph.D.Professor, Chemistry, Biochemistry and PharmacologySchool of Medicine, University of California, San Diego

Curtis C. Harris, M.D.Chief, Laboratory of Human CarcinogenesisNCI/National Institutes of Health

Note: All Board and Emeritus Board Members are also members of Keystone Symposia’s Scientific Advisory Board.

Amanda Deem, Assistant Director of DevelopmentHeather Gerhart, Senior Grants Coordinator/Program AnalystSusan Gunn, Seasonal Logistics Assistant Lindsey Heilmann, Conference CoordinatorJenny Hindorff, Program Implementation AssociateSarah Lavicka, Assistant Director of DevelopmentJeff Lehman, Scholarship CoordinatorPhyllis McNeil, Attendee Services RepresentativeAllison Ogdon, Program Development CoordinatorAnnie Page, On-Site RepresentativeMcKennzie Rains, IT Support/AssistantGrace Roath, Office ManagerJulie Roll, On-Site RepresentativeDavid Sanchez, Manager, Attendee Services Barbara Schmid-Miller, Program Implementation AssistantGwyn Schmude, Attendee Services RepresentativeDawn Shafer, Accounting ClerkBridget Stacy, Administrative Assistant, DiversityKathy Tavares, Program Development/Implementation SupervisorRebecca Wilkerson, Finance Assistant

Jacques F. Banchereau, Ph.D.

Leslie J. Browne, Ph.D. President and Chief Executive Officer Senesco Technologies, Inc.

Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer Dynavax Technologies

Max D. Cooper, M.D. Georgia Research Alliance Eminent Scholar Professor Pathology and Laboratory Medicine Pathology and Laboratory Medicine School of Medicine Emory University

Rodrigo Corrêa-Oliveira, Ph.D. Senior Researcher Laboratório de Imunologia Celular e Molecular FIOCRUZ Minas

Alan J. Cross, Ph.D. AstraZeneca Neuroscience

Martin P. Edwards, Ph.D. Vice President, Cancer Chemistry Pfizer La Jolla

I. Sadaf Farooqi, Ph.D. , F.R.C.P. Wellcome Trust Senior Clinical Fellow and Reader in Human Metabolism Metabolic Research Laboratories University of Cambridge

Ruben D. Flores-Saaib, Ph.D. Assistant Vice President Business Development Los Angeles Biomedical Research Institute

Curt R. Freed, M.D. Professor and Head Division of Clinical Pharmacology and Toxicology University of Colorado, Denver

Adolfo García-Sastre, Ph.D. Professor, Microbiology Mount Sinai School of Medicine

Tariq Ghayur, Ph.D. Senior Research Fellow, Biologics AbbVie

Margaret A. Goodell, Ph.D. Professor, Pediatrics, Hem./Onc. Director, STaR Center Center for Cell and Gene Therapy Baylor College of Medicine

Philip D. Gregory, Ph.D. Chief Scientific Officer Research Sangamo BioSciences, Inc

Diane E. Griffin, M.D., Ph.D. Professor and Chair Molecular Microbiology and Immunology Johns Hopkins Bloomberg School of Public Health

Jacqueline E. Heard, Ph.D. Venture Capital Principal Global Strategy and R&D Investments Monsanto Company

Kim A. Heidenreich, Ph.D. Professor, Department of Pharmacology University of Colorado Denver (UCHSC)

Linda Slanec Higgins, Ph.D. Vice President, Biology Gilead Sciences, Inc.

Christopher L. Karp, M.D. Deputy Director, Vaccines and Host-Pathogen Biology Global Health Discovery and Translational Sciences Bill & Melinda Gates Foundation

Laura L. Kiessling, Ph.D. Hilldale Professor of Chemistry Laurens Anderson Professor of Biochemistry Department of Chemistry and Biochemistry University of Wisconsin–Madison

Jacqueline Kirchner, Ph.D. Executive Director, Research Inflammation Amgen

Christopher Kirk, Ph.D. Vice President, Research Onyx Pharmaceuticals, Inc.

Karla Kirkegaard, Ph.D. Professor, Microbiology and Immunology Stanford University School of Medicine

Martin Kussmann, Ph.D. Head of Proteomics & Metabonomics Core Nestlé Institute of Health Sciences

Jan E. Leach, Ph.D. University Distinguished Professor Bioagricultural Sciences Colorado State University

Karolin Luger, Ph.D. Professor and HHMI Investigator Department of Molecular Biology and Biochemistry Colorado State University

Lamine Mbow, Ph.D. Director, Immunology and Inflammation Boehringer Ingelheim

Elizabeth M. McNally, M.D., Ph.D. Professor Department of Medicine and Human Genetics University of Chicago

Juanita L. Merchant, M.D., Ph.D. Professor, Internal Medicine and Molecular and Integrative Physiology University of Michigan

Tara Mirzadegan, Ph.D. Senior Director, CREATe Janssen R&D: Pharmaceutical Companies of Johnson & Johnson

Peter Mueller, Ph.D. Executive Vice President, Global Research and Development and Chief Scientific Officer Vertex Pharmaceuticals Incorporated

Dominik Mumberg, Ph.D. Director, Cell Cycle and Survival Signaling Research Global Drug Discovery Bayer HealthCare

Steven G. Nadler, Ph.D. Group Director Translational Research Immuno-Sciences Biology Drug Discovery Bristol-Myers Squibb Company

Hiroyuki Odaka, Ph.D. General Manager, Pharmaceutical Research Division Takeda Pharmaceutical Company Limited

Anne O’Garra, Ph.D., FRS, FMedSci Head, Division of Immunoregulation MRC National Institute for Medical Research

Vito J. Palombella, Ph.D. Chief Scientific Officer Infinity Pharmaceuticals, Inc.

Eric M. Parker, Ph.D. Senior Director and Neuroscience Site Lead Neuroscience and Ophthalmology Merck Research Laboratories

Mark Powers, Ph.D. Senior Director, Research & Development Primary and Stem Cell Systems Life Technologies Corporation

Ronald T. Raines, Ph.D. Professor Departments of Biochemistry and Chemistry University of Wisconsin–Madison

Murray O. Robinson, Ph.D. Senior Vice President, Translational Medicine AVEO Oncology

Cristina M. Rondinone, Ph.D. Vice President, Research and Development Head, Cardiovascular and Metabolic Diseases MedImmune

Nadia A. Rosenthal, Ph.D. Director, Australian Regenerative Medicine Institute Scientific Head, EMBL Australia Monash University

Andrej Sali, Ph.D. Professor, Bioengineering and Therapeutic Sciences University of California, San Francisco

Stephen J. Simpson, Ph.D. Director of Research Programmes & Information Research, Education and Information Arthritis Research UK

Frank J. Slack, Ph.D. Professor Molecular, Cellular and Developmental Biology Yale University

Didier Y. R. Stainier, Ph.D. Director, Developmental Genetics Max Planck Institute for Heart and Lung Research

Eric E. Swayze, Ph.D. Vice President, Medicinal Chemistry ISIS Pharmaceuticals

Doris A. Taylor, Ph.D. Director, Regenerative Medicine Research Texas Heart Institute

Joanne L. Viney, Ph.D. Vice President, Immunology Research Biogen Idec

Nicolai R. Wagtmann, Ph.D. Vice President, Head of Inflammation Biology Biopharmaceuticals Research Unit Novo Nordisk A/S

Michael J.O. Wakelam, Ph.D. Institute Director The Babraham Institute

Andrew Ward, Ph.D. Assistant Professor, Molecular Biology The Scripps Research Institute

Markus Warmuth, M.D. President and Chief Executive Officer H3 Biomedicine Inc.

Kenneth F. Wertman, Ph.D. Scientific Director, Tucson Associate Vice President, Discovery Research Chemical Analytical Sciences Sanofi US

Peter J. Worland, Ph.D. Vice President, Integrative Research Development Executive Research Celgene Corporation

Bei B. Zhang, Ph.D. General Manager, Lilly China Research & Development Co. LTD (LCRDC) Vice President, Lilly Research Laboratories Eli Lilly and Compny

Scientific Advisory Board (as of June 30, 2013)

PO Box 1630 | 160 US Highway 6, Suite 200Silverthorne, Colorado 80498 | USA

1.970.262.1230 | 1.800.253.0685 www.keystonesymposia.org